Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy
Open Access
- 1 March 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Asthma and Allergy
- Vol. ume 14, 175-178
- https://doi.org/10.2147/jaa.s300975
Abstract
Prurigo nodularis (PN) is an intense pruritic skin condition. Treatment of PN is challenging. We described an elderly patient with PN who had contradictions of cyclosporine or methotrexate and achieved significant improvement after treatment with dupilumab. We also reviewed published cases of elderly patients with PN who were refractory to traditional therapy.Keywords
This publication has 13 references indexed in Scilit:
- Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case SeriesCureus, 2020
- Dupilumab for treatment‐refractory prurigo nodularisJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2020
- Prurigo nodularisJournal of the American Academy of Dermatology, 2020
- Trial of Nemolizumab in Moderate-to-Severe Prurigo NodularisThe New England Journal of Medicine, 2020
- Efficacy of dupilumab in prurigo nodularis in elderly patientDermatologic Therapy, 2019
- Analysis of real-world treatment patterns in patients with prurigo nodularisJournal of the American Academy of Dermatology, 2019
- Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo NodularisActa Dermato-Venereologica, 2019
- Dupilumab Treatment for Generalized Prurigo NodularisJAMA Dermatology, 2019
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisThe New England Journal of Medicine, 2014
- Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigoEuropean Journal of Dermatology, 2011